|
gptkbp:instanceOf
|
gptkb:antibiotic
glycylcycline
|
|
gptkbp:activeIn
|
Gram-negative bacteria
Gram-positive bacteria
anaerobic bacteria
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01AA12
|
|
gptkbp:brand
|
gptkb:Tygacil
|
|
gptkbp:CASNumber
|
220620-09-7
|
|
gptkbp:chemicalFormula
|
C29H39N5O8
|
|
gptkbp:concerns
|
emerging resistance reported
|
|
gptkbp:contraindication
|
hypersensitivity to tetracyclines
|
|
gptkbp:developedBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
27-43 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:firstBook
|
glycylcycline antibiotics
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tigecycline
|
|
gptkbp:KEGGID
|
D06127
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits protein synthesis
binds to 30S ribosomal subunit
|
|
gptkbp:MedlinePlusID
|
a605013
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
585.65 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Pseudomonas_aeruginosa
gptkb:Proteus_species
gptkb:Providencia_species
|
|
gptkbp:notRecommendedFor
|
urinary tract infections
bloodstream infections
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
71-89%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
54686904
DB00560
|
|
gptkbp:relatedTo
|
gptkb:tetracycline
gptkb:minocycline
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
increased mortality risk
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:UNII
|
G6RGG0GU4D
|
|
gptkbp:usedFor
|
gptkb:community-acquired_bacterial_pneumonia
complicated intra-abdominal infections
complicated skin and skin structure infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Alkem_Laboratories_Ltd.
|
|
gptkbp:bfsLayer
|
7
|